Tenax Therapeutics, Inc. (TENX) Stock Analysis
A live, multi-source view of Tenax Therapeutics, Inc. (TENX): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
Sector: Healthcare · Industry: Biotechnology · United States · 14 employees · tenaxthera.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Tenax Therapeutics, Inc. (TENX) had a market capitalization of $72.6M (forward -1.3) and a beta of 0.82; the shares traded in a 52-week range of $1.31 – $19.40 (-67.9% over the year).
- Market cap
- $72.6M
- Enterprise value
- $-6.8M
- Forward P/E
- -1.3
- PEG ratio
- 1.44
- Price / book
- 0.85
- EPS (trailing)
- $-1.48
- EPS (forward)
- $-1.50
- Payout ratio
- 0.0%
- 52-week range
- $1.31 – $19.40
- 52-week change
- -67.9%
- Beta
- 0.82
- Average volume
- 4.9M
- Shares outstanding
- 37.4M
- Short % of float
- 14.75%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Tenax Therapeutics, Inc. (TENX) last closed at $2.13 (the last completed close before that scan).
Technicals at the scan: RSI 28 (oversold territory), price +11.5% versus its 20-day average, 20-day versus 50-day average spread -79.6%, MACD histogram 0.46.
Sentiment inputs: StockTwits 87% bullish; analyst consensus score 68/100.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of TENX; corporate insiders filed 7 buys and 0 sells (1 filer, latest disclosure 2026-09-08). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Adar1 Capital Management, Llc (7B/0S). Who is trading what
RapidTradeView pick record
TENX has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Tenax Therapeutics, Inc. (TENX) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell TENX.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.